| 摘要 |
The present invention relates to therapeutic combinations comprising (S)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro-2H- quinoxaline-1- carboxylic acid isopropyl ester and 4-amino-N-( (2 syn, 3S) -2-hydroxy-4- phenyl-3-( (S)-tetrahydrofuran -3-yloxycarbonylamino) -butyl) -N-isobutyl -benzenesulfonamide (amprenavir) or a physiologically functional derivative thereof, in particular (3S) tetrahydro-3-furanyl (1S,2R)-3-[ [(4-aminophenyl) sulfonyl] (isobutyl) amino]-1- benzyl-2- (phosphonooxy) propylcarbamate or calcium (3S) tetrahydro -3-furanyl (1S,2R)-3-[ [(4-aminophenyl) sulfonyl] (isobutyl)amino] -1-benzyl-2-( phosphonooxy) propylcarbamate. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HIV infections including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors of the replications of HIV. |
